Disc Medicine reports $615.9M cash; bitopertin NDA submitted for accelerated review (CNPV)

Disc Medicine, Inc.

Preliminary unaudited cash, equivalents and marketable securities of ~$615.9M as of September 30, 2025.
NDA for bitopertin in EPP submitted Sept 29, 2025; awarded FDA CNPV for 1-2 month review; potential US approval late 2025/early 2026.
Phase 2 RALLY-MF trial of DISC-0974 in anemia of MF: initial data by year-end 2025, topline data in 2026.
DISC-3405 Phase 2 PV topline data expected 2026; Phase 1b in sickle cell disease by year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.